Schering, OncoMethylome in pharmacogenomics pact
This article was originally published in Clinica
Executive Summary
Drug developer Schering-Plough and DNA methylation firm OncoMethylome Sciences have entered into a collaboration and licensing agreement to use OncoMethylome's assay technology to assess the success of Schering's brain cancer therapy, temodar (temozolomide), in patients with glioblastoma multiform (GBM). The assays could ultimately be used by doctors to determine a patient's response to the therapy.